FluoroPharma Medical, Inc. (OTC MKTS: FPMI) is a biopharmaceutical company engaged in the development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company’s initial focus is the development of breakthrough PET imaging agents, with two products advancing into clinical trials for assessment of acute and chronic forms of coronary artery disease. The company is also developing agents for imaging specific cancers. For more information, visit the company’s website at www.fluoropharma.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.